- Target disease: human African trypanosomiasis (sleeping sickness)
- Main partners (since project start): Anacor Pharmaceuticals Inc., Pace University, USA; The Laboratory of Microbioloy, Parasitology, and Hygiene, University of Antwerp, Belgium; SCYNEXIS Inc., USA.
- Project start: April 2007 and April 2009, respectively
- Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations & individuals.
Extensive pharmacokinetic profiling of possible oxaborole compounds led to the selection of SCYX-1608210 and SCYX‑1330682, which demonstrated cure in the stage 2 mouse model of HAT, as a backup for acoziborole (SCYX-7158) in case of need. Given the current success of other projects for HAT, further development was put on hold in 2013 and will only recommence should problems be encountered with acoziborole (SCYX-7158) in clinical development.
DNDi continues to provide support and advice to researchers working on discovery of new candidates for HAT and maintains two back-up candidates from the oxaborole class to ensure future development options, if needed.
Last update: August 2019